SEC Form 4 · accession 0001209191-17-059331
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Officer — EVP & Chief Commercial Officer
Period of report
Nov 2, 2017
Accepted (ET)
Nov 3, 2017 · 7:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2017 | M | 6,666 | $25.29 | A | 79,998 | D | |
| Common StockF1 | Nov 2, 2017 | S | 6,666 | $54.95 | D | 73,332 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $25.29 | Nov 2, 2017 | M | 6,666 | D | — | Nov 7, 2026 | Common Stock | 6,666 | 33,334 | D |
Explanation of responses
- F1The sales and related option exercises reported on this Form 4 were executed pursuant to a trading plan adopted by the reporting person on March 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934.
- F21/48th of the shares subject to the option became vested and exercisable on December 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter.